WO2021137148A1 - Dosage regime with esketamine for treating neuropsychiatric or neurological conditions - Google Patents
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions Download PDFInfo
- Publication number
- WO2021137148A1 WO2021137148A1 PCT/IB2020/062508 IB2020062508W WO2021137148A1 WO 2021137148 A1 WO2021137148 A1 WO 2021137148A1 IB 2020062508 W IB2020062508 W IB 2020062508W WO 2021137148 A1 WO2021137148 A1 WO 2021137148A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- less
- esketamine
- administration
- disorder
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present disclosure provides methods for safe and efficacious administration of esketamine.
- Ketamine is a non-barbiturate, rapid acting, induction and general anesthetic agent that acts primarily via NMD A receptor antagonism in the CNS.
- the drug has been available in the United States since 1970 under the tradename Ketalar ® .
- DE2062620 described ketamine’s (-) enantiomer, esketamine.
- Esketamine is available in Europe as an induction and general anesthetic agent under the tradename Ketanest ® S and in the US as a nasal spray, to be used in conjunction with an oral antidepressant, to treat treatment-resistant depression under the tradename Spravato ® .
- DEI 02007009888 suggests the use of (S)(+)-ketamine in the treatment of depression. More recently, there has been an increased interest in the possibility of using ketamine or esketamine for the treatment of major depressive disorder (MDD) including when the depression has proved refractory to other therapies leading, in 2019, to a first marketing approval for the enantiomer to treat depression.
- MDD major depressive disorder
- Ketamine and esketamine have also been investigated in a variety of other neurological and psychiatric conditions.
- Diazgranados et al (2010) demonstrated a robust and rapid effect of intravenous ketamine in bipolar disorder
- Glue et al found an improvement in anxiety ratings within an hour of ketamine dosing which persisted for up to a week in treatment-refractory Generalized Anxiety and Social Anxiety Disorder patients
- Sherman et al (2016) found that ketamine could reduce levodopa induced dyskinesia in Parkinson’s disease sufferers and Marchetti et al (2015) showed that oral ketamine could reduce chronic pain.
- compositions of ketamine and esketamine have been administered to healthy subjects and patients via a variety of roots of administration including intravenously, intranasally and orally.
- Clements et al (1982) record the relative bioavailability of oral ketamine as being 17% and of intramuscular ketamine as being 93%. Since that article, several other studies have recorded the relative oral bioavailability of ketamine as being between 17 and 24%.
- Malinovsky et al (1996) record the relative bioavailability of intranasal ketamine as being 50% and of rectal ketamine as being 30%.
- Yanagihara et al (2003) record the relative bioavailability of both rectal and sublingual ketamine as being 30%, whereas they found nasal bioavailability to be 45%.
- W02019126108 discloses that 56 mg and 84 mg administered intranasally produces plasma esketamine levels at or above the range achieved by an intravenous administration of 0.2 mg/kg of esketamine, suggesting that the relative bioavailability of intranasal esketamine might be lower than that of ketamine.
- the invention relates to a method of treating a condition other than major depressive disorder (MDD) in a human patient in need thereof comprising orally administering to said patient an oral dosage form comprising between about 5 mg and about 40 mg of esketamine over a treatment regimen of at least 28 days.
- MDD major depressive disorder
- the present invention is directed to methods of treating a condition other than major depressive disorder in a human patient in need thereof comprising orally administering to said patient an oral dosage form comprising about 5 mg to about 40 mg ( e.g 5 mg to 40 mg) of esketamine over a treatment regimen of at least 28 days.
- the term “major depressive disorder”, or MDD is characterized as a psychiatric disorder meeting five criteria: 1) the presence during the same 2 week period which together represent a change from previous functioning, of a depressed/sad mood or a loss of interest and pleasure, together with five (or more) of the following additional criteria occurring nearly every day i) depressed/sad mood ii) loss of interest and pleasure iii) significant weight loss when not dieting or weight gain or a decrease or increase in appetite iv) insomnia or hypersomnia v) psychomotor agitation or retardation vi) fatigue or loss of energy vii) feelings of worthlessness or excessive or inappropriate guilt viii) diminished ability to think or concentrate or indecisiveness ix) recurrent thoughts of death or suicidal ideation, planning or attempt: 2) the symptoms cause clinically significant distress or impairment in social, occupational or other functioning: 3) the episode is not better accounted for by a psychotic disorder: 4) the episode is not attributable
- the condition other than major depressive disorder is a neuropsychiatric condition and/or a neurological condition.
- the neuropsychiatric condition is selected from the group consisting of acute stress disorder, alcohol dependence disorder, alcohol use disorder, anorexia nervosa, anxiety disorders, bipolar disorder, borderline personality disorder, bulimia nervosa, PMDD, schizoaffective disorder and schizophrenia.
- the neurological condition is selected from the group consisting of ALS, Alzheimer's disease, chronic fatigue, diabetic neuropathy, dyskinesia, fibromyalgia, opioid tolerance, pain and traumatic brain injury.
- neuropsychiatric condition shall refer to a psychiatric condition as catalogued and characterized by the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders fifth edition 2013 (DSM-5).
- acute stress disorder shall refer to a neuropsychiatric condition in which an individual has been exposed to actual or threatened death, serious injury and/or sexual violation and presenting with symptoms of intrusion, negative mood, dissociation, avoidance, and arousal lasting from 3 days to 1 month following exposure to the traumatic events.
- treating acute stress disorder can refer to a reduction of the symptoms of acute stress.
- treating acute stress disorder refers to a decrease in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score, an increase in time to worsening of Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score, a decrease in Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) score, an increase in time to worsening of Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) score, a decrease in Posttraumatic Diagnostic Scale -5 (PDS- 5) score, an increase in time to worsening of Posttraumatic Diagnostic Scale -5 (PDS-5) score, a decrease in PTSD Symptom Scale - Interview for DSM-5 (PSS-I-5) score, an increase in time to worsening of PTSD Symptom Scale - Interview for DSM-5 (PSS-I-5) score, a decrease in National Stressful Events Survey A
- alcohol dependence disorder shall refer to a neuropsychiatric condition in which an individual is physically or psychologically dependent upon alcohol, as catalogued and characterized by the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders fourth edition 1995 (DSM-4).
- treating alcohol dependence disorder can refer to a reduction of the symptoms of alcohol dependence.
- treating alcohol dependence refers to a decrease in the number of Heavy Drinking Days (HDDs) from baseline, an increase in alcohol abstinence rates, a reduction in Drinking Risk Level (RSDRL) response, a decrease in the World Health Organization (WHO) Drinking Risk Category of at least one level, a decrease in the percentage of days abstinent alcohol per week, a decrease in the percentage of days of heavy drinking per week, a decrease in the mean number of drinks per week, a decrease in Alcohol Craving Scale - Short Form (ACQ-SR-R) score, an increase in time to worsening of Alcohol Craving Scale - Short Form (ACQ- SR-R) score, a decrease in Alcohol Related Consequences (ImBIBe) score, an increase in time to worsening of Alcohol Related Consequences (ImBIBe) score, an increase in the number of patients
- HDDs Heavy Drinking Days
- RDRL Drinking
- alcohol use disorder can refer to a neuropsychiatric condition in which an individual partakes in heavy alcohol use and suffers from a loss of control over alcohol intake.
- treating alcohol use disorder can refer to a reduction of the symptoms of alcohol dependence.
- treating alcohol dependence refers to a reduction in the number of Heavy Drinking Days (HDDs) from baseline, an increase in alcohol abstinence rates, a decrease in Drinking Risk Level (RSDRL) response, a decrease in the World Health Organization (WHO) Drinking Risk Category of at least one level, a decrease in the percentage of days abstinent alcohol per week, a decrease in the percentage of days of heavy drinking per week, a decrease in the mean number of drinks per week, a decrease in Alcohol Craving Scale - Short Form (ACQ-SR-R) score, an increase in time to worsening of Alcohol Craving Scale - Short Form (ACQ-SR-R) score, a decrease in Alcohol Related Consequences (ImBIBe) score, an increase in time to worsening of Alcohol Related Consequences (ImBIBe) score, an increase in the number of patients reaching
- HDDs Heavy Drinking Days
- RDRL Drinking
- anorexia nervosa can refer to a neuropsychiatric condition in which an individual suffers from persistent energy intake restriction, intense fear of gaining weight or of becoming fat, or persistent behavior that interferes with weight gain, and a disturbance in self- perceived body weight or shape.
- treating anorexia nervosa can refer to a reduction of the symptoms of anorexia nervosa.
- treating anorexia nervosa refers to an increase from baseline in body weight, an increase from baseline in appetite, an increase in Body Mass Index (BMI), a decrease in the obsessions subscale of the Yale-Brown Obsessive Compulsive Scale score, an increase in time to worsening of obsessions subscale of the Yale-Brown Obsessive Compulsive Scale score, a decrease in Eating Disorder Inventory Drive for Thinness subscale score, an increase in time to worsening of Eating Disorder Inventory Drive for Thinness subscale score, a decrease in Eating Disorder Inventory (EDI) score for Body Dissatisfaction, an increase in time to worsening of Eating Disorder Inventory (EDI) score for Body Dissatisfaction, a decrease in Ease of Eating Scale (EOES) score, an increase in time
- anxiety disorders refers to neuropsychiatric conditions that share features of excessive fear and/or anxiety and related behavioral disturbances.
- anxiety disorders include Generalized Anxiety Disorder, Social Anxiety Disorder, agoraphobia, Panic Disorder and phobias.
- treating anxiety disorders refers to a reduction in the symptoms of anxiety disorders.
- treating anxiety disorders refers to the treatment of Generalized Anxiety Disorder.
- treating anxiety disorders refers to the treatment of Social Anxiety Disorder.
- treating anxiety disorders refers to the treatment of agoraphobia.
- treating anxiety disorders refers to the treatment of Panic Disorder.
- treating anxiety disorders refers to the treatment of specific phobias.
- treating Generalized Anxiety Disorder can refer to a reduction of the symptoms of Generalized Anxiety Disorder.
- treating Generalized Anxiety Disorder refers to a decrease in Hamilton Anxiety Scale (HAM- A) score, an increase in time to worsening of Hamilton Anxiety Scale (HAM-A) score, a decrease in Hospital Anxiety and Depression (HAD) anxiety subscale score, an increase in time to worsening of Hospital Anxiety and Depression (HAD) anxiety subscale score, an increase in the percentage of responders in HAM-A, an increase in the number of patients reaching remission, a decrease in Generalized Anxiety Disorder 7 items scale (GAD-7) score, an increase in time to worsening of Generalized Anxiety Disorder 7 items scale (GAD-7) score, a decrease in 36-Item Short-Form Health Survey (SF-36) Social Functioning subscore, a decrease in the number of DSM-5 diagnostic criteria, a decrease in the frequency of presentation of DSM
- treating Social Anxiety Disorder can refer to a reduction of the symptoms of Social Anxiety Disorder.
- treating Social Anxiety Disorder refers to a decrease in Liebowitz Social Anxiety Scale (LSAS) score, an increase in time to worsening of Liebowitz Social Anxiety Scale (LSAS) score, a decrease in Brief Social Phobia Scale (BSPS) score, an increase in time to worsening of Brief Social Phobia Scale (BSPS) score, a decrease in Marks Fear questionnaire social anxiety subscore, an increase in time to worsening of Marks Fear questionnaire social anxiety subscore, a decrease in Fear of Negative Evaluation (FNE) score, an increase in time to worsening of Fear of Negative Evaluation (FNE) score, a decrease in Albany Panic and Phobia Questionnaire (APPQ) Social Anxiety subscore, an increase in time to worsening of Albany Panic and Phobia Questionnaire (APPQ) Social Anxiety subscore, an increase in time to worsening of Albany Panic and Phobia
- treating agoraphobia can refer to a reduction of the symptoms of agoraphobia.
- treating agoraphobia refers to a decrease in Panic and Agoraphobia Scale (PAS) score, an increase in time to worsening of Panic and Agoraphobia Scale (PAS) score, a decrease in Albany Panic and Phobia Questionnaire (APPQ) agoraphobia subscore, an increase in time to worsening of Albany Panic and Phobia Questionnaire (APPQ) agoraphobia subscore, an increase in the number of patients reaching remission, a decrease in Ost Agoraphobia Scale (AS) score, a decrease in the number of DSM-5 diagnostic criteria, a decrease in the frequency of presentation of DSM-5 diagnostic criteria and/or an increase in time to worsening of Ost Agoraphobia Scale (AS) score.
- PAS Panic and Agoraphobia Scale
- APPQ Albany Panic and Phobia Questionnaire
- treating Panic Disorder can refer to a reduction of the symptoms of Panic Disorder.
- treating Panic Disorder refers to a reduction in the frequency of panic attacks, a reduction in the duration of panic attacks, a decrease in Panic Disorder Severity Scale (PDSS) score, an increase in time to worsening of Panic Disorder Severity Scale (PDSS) score, an increase in the number of patients reaching remission, a decrease in Albany Panic and Phobia Questionnaire (APPQ) Panic Disorder subscore, a decrease in the number of DSM-5 diagnostic criteria, a decrease in the frequency of presentation of DSM-5 diagnostic criteria and/or an increase in time to worsening of Albany Panic and Phobia Questionnaire (APPQ) Panic Disorder subscore.
- PDSS Panic Disorder Severity Scale
- APPQ Albany Panic and Phobia Questionnaire
- treating phobias can refer to a reduction of the symptoms of a phobia.
- treating phobias refers to a decrease in VAS-Anxiety score, an increase in time to worsening of VAS-Anxiety score, a decrease in State-Trait Anxiety Inventory (STAI) score, an increase in time to worsening of State-Trait Anxiety Inventory (STAI) score, a decrease in Beck Anxiety Inventory (BAI) score, an increase in time to worsening of Beck Anxiety Inventory (BAI) score, a decrease in Fairbrother and Antony Specific Phobia Questionnaire (SPQ) score, an increase in time to worsening of Fairbrother and Antony Specific Phobia Questionnaire (SPQ) score, a decrease in Acute Panic Inventory (API) score, an increase in time to worsening of Acute Panic Inventory (API) score, a decrease in Profile of Mood States (POMS) score, an increase
- VAS-Anxiety score an increase in time to
- the present invention is further directed to methods of treating bipolar disorder in a human patient in need thereof comprising orally administering to said patient an oral dosage form comprising about 5 mg to about 40 mg (e.g., 5 mg to 40 mg) of esketamine over a treatment regimen of at least 28 days.
- bipolar disorder can refer to a neuropsychiatric disorder in which an individual suffers from significant mood episodes including mania and/or hypomania and/or depression and with, or without, mixed features (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, (DSM-V) American Psychiatric Association, 2013).
- bipolar disorder includes bipolar I disorder, bipolar II disorder and cyclothymic disorder.
- bipolar I disorder is characterized as a psychiatric disorder comprising a manic episode wherein the manic episode may have been preceded by and/or followed by hypomanic and/or major depressive episodes.
- bipolar II disorder is characterized as a psychiatric disorder comprising a current, or past, hypomanic episode and a current, or past, major depressive episode.
- the term “mood episode” is a cluster of symptoms that occur for a discreet period of time, is typically associated with bipolar disorder and includes manic episodes, hypomanic episodes and major depressive episodes.
- the term “manic episode” comprises four criteria: 1) a distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased goal-directed activity or energy, lasting at least one week and present most of the day, nearly every day or of any duration if hospitalization is necessary; 2) during the period of mood disturbance and increased energy or activity, three or more of the following symptoms (four if the mood is only irritable) are present to a significant degree and represent a noticeable change from usual behavior: i) inflated self-esteem or grandiosity, ii) decreased need for sleep, iii) more talkative than usual or pressure to keep talking, iv) flight of ideas or subjective experience that thoughts are racing, v) distractibility as reported or observed, vi) increase in goal-directed activity, either socially, at work or school, or sexually or psychomotor agitation and vii) excessive involvement in activities that have a high potential for painful consequences; 3) the mood disturbance is sufficiently severe to cause marked impairment in social or occupational
- the term “hypomanic episode” comprises six criteria: 1) a distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least four consecutive days and present most of the day, nearly every day; 2) during the period of mood disturbance and increased energy and activity, three or more of the following symptoms (four if the mood is only irritable) have persisted, represent a noticeable change from usual behavior, and have been present to a significant degree: i) inflated self-esteem or grandiosity, ii) decreased need for sleep, iii) more talkative than usual or pressure to keep talking, iv) flight of ideas or subjective experience that thoughts are racing, v) distractibility as reported or observed, vi) increase in goal-directed activity either socially, at work or school, or sexually or psychomotor agitation and vii) excessive involvement in activities that have a high potential for painful consequences; 3) the episode is associated with an unequivocal change in functioning that is uncharacteristic of
- the term “major depressive episode” comprises three criteria: 1) five or more of the following symptoms have been present during the same two-week period and represent a change from previous functioning and wherein at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure and do not include symptoms that are clearly attributable to another medical condition: i) depressed mood most of the day, nearly every day, as indicated by either subjective report or observation made by others, ii) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day as indicated by either subjective account or observation, iii) significant weight loss when not dieting or weight gain or a decrease or increase in appetite nearly every day, iv) insomnia or hypersomnia nearly every day, v) psychomotor agitation or retardation nearly every day which is observable by others and not merely subjective feelings of restlessness or being slowed down, vi) fatigue or loss of energy nearly every day, vii) feelings of worthlessness or excessive or inappropriate guilt, which may be delus
- cyclothymic disorder is characterized as a psychiatric disorder comprising five criteria: 1) for at least two years there have been numerous periods with hypomanic symptoms that do not meet criteria for a hypomanic episode and numerous periods with depressive symptoms that do not meet criteria for a major depressive episode and wherein said symptoms are not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified or unspecified schizophrenia spectrum or other psychotic disorders; 2) during said two-year period, the hypomanic and depressive periods have been present for at least half the time and the individual has not been without the symptoms for more than two months at a time; 3) the criteria for a major depressive, manic, or hypomanic episode have never been met; 4) the symptoms are not attributable to the physiological effects of a substance or another medical conditio; and, 5) the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- the bipolar disorder is with anxious distress.
- the disorder is with mixed features.
- the disorder is with melancholic features.
- the disorder is with atypical features.
- the disorder is with mood-congruent psychotic features.
- the disorder is with mood-incongruent psychotic features.
- the disorder is with catatonia.
- the disorder is with peripartum onset.
- the disorder is with seasonal pattern.
- treating bipolar disorder can refer to a reduction and/or prevention of the symptoms of bipolar disorder.
- treating bipolar disorder refers to the treatment of bipolar I disorder.
- treating bipolar disorder refers to the treatment of bipolar II disorder.
- treating bipolar disorder refers to the treatment of cyclothymic disorder.
- treating bipolar disorder can refer to maintenance therapy of bipolar disorder.
- treating bipolar disorder can refer to the treatment of major depressive episodes, and their symptoms, as associated with bipolar disorder.
- treating bipolar disorder refers to a decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score in patients suffering from bipolar disorder, an increase in time to worsening of Montgomery-Asberg Depression Rating Scale (MADRS) score in patients suffering from bipolar disorder, a decrease in Hamilton Depression Rating Scale score in patients suffering from bipolar disorder, an increase in time to worsening of Hamilton Depression Rating Scale score in patients suffering from bipolar disorder, a decrease in clinically relevant recurrences of depression, a reduction in clinically relevant recurrences of mania, a decrease in Young Mania Rating Scale (YMRS) score, an increase in time to worsening of Young Mania Rating Scale (YMRS) score, a decrease in Clinical Global Impressions (CGI) Scale for use in bipolar illness (CGI-BP) score, an increase in time to worsening of Clinical Global Impressions (CGI) Scale for use in bipolar illness (CGI-BP) score, a decrease in Beck depression inventory score,
- said increases, decreases and reductions of scores and/or presentations of symptoms can be assessed in comparison to the scores and/or presentations of symptoms as identified before treatment is initiated, i.e. baseline. In another embodiment, said increases, decreases and reductions of scores and/or presentations of symptoms can be assessed in comparison to the scores and/or presentations of symptoms as identified in a different treatment group.
- the different treatment group is a second medication other than ketamine or esketamine. In another embodiment, the different treatment group is a placebo.
- the bipolar disorder has not responded to adequate doses and treatment duration of antidepressants other than ketamine or esketamine.
- the non responder has failed to demonstrate an improvement of up to 25% in MADRS score, a similar psychometric score or in patient self-reporting of their global impression of improvement, after adequate doses and treatment duration of antidepressants other than ketamine or esketamine.
- the non-responder has demonstrated an incomplete improvement of between 25 - 50% in MADRS score, a similar psychometric score or in patient self-reporting of their global impression of improvement, after adequate doses and treatment duration of antidepressants other than ketamine or esketamine.
- the non-responder has demonstrated an inadequate improvement of up to 50% in MADRS score, a similar psychometric score or in patient self-reporting of their global impression of improvement, after adequate doses and treatment duration of antidepressants other than ketamine or esketamine.
- the adequate doses and treatment duration of antidepressants other than ketamine or esketamine refers to doses and treatment duration of one, or more, antidepressants other than ketamine or esketamine during the current major depressive episode.
- the adequate course refers to the non-response to doses and treatment duration of one, or more, antidepressants other than ketamine or esketamine during a previous major depressive episode.
- the adequate course refers to the non-response to doses and treatment duration of one, or more, antidepressants other than ketamine or esketamine both during a previous major depressive episode and during the current major depressive episode.
- the disorder is treatment-refractory or treatment-resistant bipolar depression, i.e., bipolar depression that has failed to respond to adequate doses and treatment duration of at least two antidepressants other than ketamine or esketamine.
- the bipolar disorder has not responded to adequate doses and treatment duration of an antimanic agent.
- the non-responder has failed to demonstrate an improvement of up to 25% in MADRS score, a similar psychometric score or in patient self- reporting of their global impression of improvement, after adequate doses and treatment duration of an antimanic agent.
- the non-responder has demonstrated an incomplete improvement of between 25 - 50% in MADRS score, a similar psychometric score or in patient self-reporting of their global impression of improvement, after adequate doses and treatment duration of an antimanic agent.
- the non-responder has demonstrated an inadequate improvement of up to 50% in MADRS score, a similar psychometric score or in patient self-reporting of their global impression of improvement, after adequate doses and treatment duration of an antimanic agent.
- the adequate doses and treatment duration of an antimanic agent refers to doses and treatment duration of one, or more, antimanic agents during the current major depressive episode.
- the adequate course refers to the non-response to doses and treatment duration of one, or more, antimanic agents during a previous major depressive episode.
- the adequate course refers to the non-response to doses and treatment duration of one, or more, antimanic agents both during a previous major depressive episode and during the current major depressive episode.
- borderline personality disorder can refer to a neuropsychiatric disorder in which an individual suffers from a pervasive pattern of instability of interpersonal relationships, self-image, affects, and marked impulsivity and which begins by early adulthood.
- treating borderline personality disorder can refer to a reduction of the symptoms of borderline personality disorder.
- treating borderline personality disorder refers to a decrease in Clinical Interview Schedule-Revised (CIS-R) score, an increase in time to worsening of Clinical Interview Schedule-Revised (CIS-R) score, a decrease in the Clinical Interview for Depression score, an increase in time to worsening Clinical Interview for Depression score, of an increase in the number of patients reaching remission, a decrease in the Clinical Interview for Mania score, a decrease in the number of DSM-5 diagnostic criteria, a decrease in the frequency of presentation of DSM-5 diagnostic criteria and/or an increase in time to worsening of Clinical Interview for Mania score.
- the term “bulimia nervosa” can refer to a neuropsychiatric condition in which an individual suffers from recurrent episodes of binge eating, recurrent inappropriate compensatory behaviors to prevent weight gain and self-evaluation that is unduly influenced by body shape and weight.
- treating bulimia nervosa can refer to a reduction of the symptoms of bulimia nervosa.
- treating bulimia nervosa refers to a an increase from baseline in body weight, an increase from baseline in appetite, an increase in Body Mass Index (BMI), a decrease in the obsessions subscale of the Yale-Brown Obsessive Compulsive scale, an increase in time to worsening of Yale-Brown Obsessive Compulsive scale, a decrease in Eating Disorder Inventory Drive for Thinness subscale, an increase in time to worsening of Eating Disorder Inventory Drive for Thinness subscale, a decrease in Eating Disorder Inventory (EDI) score for Body Dissatisfaction, an increase in time to worsening of Eating Disorder Inventory (EDI) score for Body Dissatisfaction, a decrease in Ease of Eating Scale (EOES) score, an increase in time to worsening of Ease of
- premenstrual dysphoric disorder can refer to a neuropsychiatric condition in which an individual suffers from expressions of mood lability, irritability, dysphoria, and anxiety symptoms that occur repeatedly during the premenstrual phase of the cycle and remit around the onset of menses or shortly thereafter.
- treating PMDD can refer to a reduction of the symptoms of
- treating PMDD refers to a decrease in Daily Record of Severity of Problems (DRSP) score, an increase in time to worsening of Daily Record of Severity of Problems (DRSP) score, a decrease in the incidence of treatment emergent adverse events, an increase in the number of patients reaching remission, a decrease in the number of DSM-5 diagnostic criteria, a decrease in the frequency of presentation of DSM-5 diagnostic criteria and/or a decrease in migraine pain scale score for a single menstrual migraine attack.
- DRSP Daily Record of Severity of Problems
- DRSP Daily Record of Severity of Problems
- schizoaffective disorder can refer to a neuropsychiatric condition in which an individual suffers from an uninterrupted period of illness during which the individual continues to display active or residual symptoms of psychotic illness.
- schizoaffective disorder includes both bipolar and depressive schizoaffective disorder types.
- treating schizoaffective disorder can refer to a reduction of the symptoms of schizoaffective disorder.
- treating schizoaffective disorder refers to a decrease in Positive and Negative Symptoms of Schizophrenia (PANSS) score, an increase in time to worsening of Positive and Negative Symptoms of Schizophrenia (PANSS) score, a decrease in Scale for the Assessment of Negative Symptoms (SANS) score, an increase in time to worsening of Scale for the Assessment of Negative Symptoms (SANS) score, a decrease in Scale for the Assessment of Positive Symptoms (SAPS) score, an increase in time to worsening of Scale for the Assessment of Positive Symptoms (SAPS) score, a decrease in Clinical Global Impression (CGI-S-SCA) Severity for Schizoaffective Disorder score, an increase in time to worsening of Clinical Global Impression (CGI-S-SCA) Severity for Schizoaffective Disorder score, an increase in time to worsen
- schizophrenia can refer to a neuropsychiatric condition in which an individual suffers from a range of cognitive, behavioral, and emotional dysfunctions including the clear presence of delusions, hallucinations and/or disorganized speech.
- treating schizophrenia can refer to a reduction of the symptoms of schizophrenia.
- treating schizophrenia refers to a decrease in Positive and Negative Symptoms of Schizophrenia (PANSS) score, an increase in time to worsening of Positive and Negative Symptoms of Schizophrenia (PANSS) score, a decrease in Scale for the Assessment of Negative Symptoms (SANS) score, an increase in time to worsening of Scale for the Assessment of Negative Symptoms (SANS) score, a decrease in Scale for the Assessment of Positive Symptoms (SAPS) score, an increase in time to worsening of Scale for the Assessment of Positive Symptoms (SAPS) score, a decrease in Clinical Global Impression (CGI-S) Severity score, an increase in time to worsening of Clinical Global Impression (CGI-S) Severity score, an increase in Personal and Social Performance (PSP) score, an increase in time to worsening of Personal and Social Performance (PSP)
- CGI-S Clinical Global Impression
- neurological condition can refer to a disease of the central and/or peripheral nervous system.
- ALS Amyotrophic Lateral Sclerosis
- ALS can refer to a neurological condition affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord.
- the condition can manifest clinically as progressive weakness, atrophy, fasciculation, hyperreflexia, dysarthria, dysphagia, and eventual paralysis of respiratory function.
- treating ALS can refer to a reduction of the symptoms of
- treating ALS refers to a decrease in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score, an increase in time to worsening of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score, an increase in Ventilation Assistance- free Survival (VAFS) time, an increase in overall survival time, an increase in muscle strength as measured by Handheld Dynamometry (HHD), a decrease in Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) score, an increase in time to worsening of Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) score, a decrease in Amyotrophic Lateral Sclerosis Assessment Questionnaire- 5 (ALSAQ-5) score, an increase in time to worsening of Amyotrophic Lateral Sclerosis Assessment Questionnaire- 5 (ALSAQ-5) score, an increase in Progression Free Survival (PFS) time, a decrease in Norris ALS scale score, an increase in time to worsening of
- Alzheimer's Disease can refer to a neurological condition affecting the brain characterized by the insidious onset of dementia.
- the condition can manifest clinically as impairment of memory, judgment, attention span, and problem solving skills, severe apraxias and a global loss of cognitive abilities.
- treating Alzheimer’s Disease can refer to a reduction of the symptoms of Alzheimer’s Disease.
- treating Alzheimer’s Disease refers to a decrease in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score, an increase in time to worsening of Clinical Dementia Rating - Sum of Boxes (CDR-SB) score, a decrease in Alzheimer's Disease Composite Score (ADCOMS), an increase in time to worsening of Alzheimer's Disease Composite Score (ADCOMS), an increase in time to worsening of Clinical Dementia Rating (CDR) score, an increase in time to worsening of Clinical Dementia Rating (CDR) score, an increase in Mini-Mental State Exam (MMSE) score, an increase in time to worsening of Mini-Mental State Exam (MMSE) score, a decrease in Alzheimer’s Disease Assessment Scale Cognitive subscale (ADAS-Cog) score, an increase in time to worsening of Alzheimer’s Disease Assessment Scale Cognitive subscale (ADAS-Cog) score, an
- chronic fatigue can refer to a neurological condition characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment wherein said symptoms are not caused by ongoing exertion and are not relieved by rest.
- chronic fatigue is a clinical presentation secondary to another pathology wherein said pathology can include cancer, depression, bipolar disorder, Parkinson’s disease and fibromyalgia.
- treating chronic fatigue can refer to a reduction of the symptoms of chronic fatigue.
- treating chronic fatigue refers to a decrease in Multidimensional Fatigue Inventory (MFI) - general fatigue subscale score, an increase in time to worsening of Multidimensional Fatigue Inventory (MFI) - general fatigue subscale score, a decrease in Brief Pain Inventory (BPI) - average pain severity score, an increase in time to worsening of Brief Pain Inventory (BPI) - average pain severity score, a decrease in Hospital Anxiety and Depression Scale (HADS) - depression subscale score, an increase in time to worsening of Hospital Anxiety and Depression Scale (HADS) - depression subscale score, a decrease in Checklist Individual Strength (CIS) score, an increase in time to worsening of Checklist Individual Strength (CIS) score and/or an increase in the percentage of patients with 20% or greater improvement in CIS total score.
- MFI Multidimensional Fatigue Inventory
- BPI Brief Pain Inventory
- BPI Brief Pain Inventory
- HADS Hospital Anxiety and Depression Scale
- diabetes neuropathy can refer to a neurological condition affecting peripheral, autonomic, and cranial nerves that are associated with diabetes mellitus.
- treating diabetic neuropathy can refer to a reduction of the symptoms of diabetic neuropathy.
- treating diabetic neuropathy refers to a decrease in Utah Early Neuropathy Scale (UENS) score, an increase in time to worsening of Utah Early Neuropathy Scale (UENS) score, a decrease in Norfolk Quality of Life-Diabetes Neuropathy (NQoL- DN) score, an increase in time to worsening of Norfolk Quality of Life-Diabetes Neuropathy (NQoL- DN) score, a decrease in Neuropathy Impairment Score of the Lower Limb (NIS-LL) score, an increase in time to worsening of Neuropathy Impairment Score of the Lower Limb (NIS-LL) score, a decrease in Michigan Diabetic Neuropathy (MNDS) score, an increase in time to worsening of Michigan Diabetic Neuropathy (MNDS) score, a decrease in modified Toronto Clinical Neuropathy Scale (mTCNS) score and/or an increase in time to worsen
- dyskinesia can refer to a neurological condition characterized by abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that typically occur as a manifestation of an underlying disease process.
- the dyskinesia is levodopa induced dyskinesia.
- treating dyskinesias can refer to a reduction of the symptoms of dyskinesias.
- treating dyskinesias refers to a decrease in Abnormal Involuntary Movement Scale (AIMS) score, an increase in time to worsening of Abnormal Involuntary Movement Scale (AIMS) score, a decrease in Unified Dyskinesia Rating Scale (UDysRS) score, an increase in time to worsening of Unified Dyskinesia Rating Scale (UDysRS) score, a decrease in Rush Dyskinesia Rating Scale (RDRS) score, an increase in time to worsening of Rush Dyskinesia Rating Scale (RDRS) score increase, a decrease in Lang-Lahn Activities of Daily Living Dyskinesia Rating Scale (LL) score, an increase in time to worsening of Lang-Lahn Activities of Daily Living Dyskinesia Rating Scale (LL).
- fibromyalgia can refer to a neurological condition characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points) wherein muscle pain can be aggravated by inactivity or exposure to cold.
- fibromyalgia can manifest clinically with general symptoms, such as sleep disturbances, fatigue, stiffness, headaches, and occasionally depression.
- treating fibromyalgia can refer to a reduction of the symptoms of fibromyalgia.
- treating fibromyalgia refers to a decrease in Fibromyalgia Impact Questionnaire - Revised (FIQ-R) score, an increase in time to worsening of Fibromyalgia Impact Questionnaire - Revised (FIQ-R) score, an increase in Daily Sleep Interference (DSIS) score, an increase in time to worsening of Daily Sleep Interference (DSIS) score, a decrease in Pain Intensity-Numerical Rating Scale (PI-NRS) score and/or an increase in time to worsening of Pain Intensity-Numerical Rating Scale (PI-NRS) score.
- opioid tolerance can refer to a neurological condition characterized by a patient’s tolerance to opioid’s analgesic and other effects typically leading to a reduction in analgesic efficacy and dose escalations.
- treating opioid tolerance can refer to a reduction of the symptoms of opioid tolerance.
- treating opioid tolerance refers to a decrease in opioid consumption, to an increase in a decrease in average pain intensity, to a decrease in worst pain intensity, to a decrease in rescue medication consumption, a decrease in the frequency of administration of rescue medication, a decrease in Brief Pain Inventory (BPI) average pain score, a decrease in Brief Pain Inventory (BPI) worst pain score, a decrease in Summed Pain Intensity Difference (SPID) score, an increase in Total Pain Relief (TOTPAR) score, a decrease in time to peak pain relief, a decrease in time to first perceptible pain relief, a decrease in time to meaningful pain relief and/or a decrease in Average Daily Pain (ADPS) score.
- BPI Brief Pain Inventory
- SPID Summed Pain Intensity Difference
- TOTPAR Total Pain Relief
- the term “pain” can refer to a neurological condition characterized by an unpleasant sensation induced by noxious stimuli.
- the pain is neuropathic pain.
- the pain is nociceptive pain.
- the term “neuropathic pain” can refer to pain associated with damage to, or disease affecting, the nervous system and can be either central, peripheral or mixed central and peripheral.
- the term “nociceptive pain” can refer to pain associated with stimulation of sensory nerve fibers and can be either superficial, deep or a mixture of the two.
- the pain is acute pain.
- the pain is chronic pain.
- treating pain can refer to a reduction of the symptoms of pain.
- treating pain refers to a decrease in average pain intensity, to a decrease in worst pain intensity, to a decrease in opioid consumption, to a decrease in rescue medication consumption, a decrease in the frequency of administration of rescue medication, a decrease in Brief Pain Inventory (BPI) average pain score, an increase in time to worsening of Brief Pain Inventory (BPI) average pain score, a decrease in Brief Pain Inventory (BPI) worst pain score, an increase in time to worsening of Brief Pain Inventory (BPI) worst pain score, a decrease in Summed Pain Intensity Difference (SPID) score, an increase in time to worsening of Summed Pain Intensity Difference (SPID) score, an increase in Total Pain Relief (TOTPAR) score, an increase in time to worsening of Total Pain Relief (TOTPAR) score, a decrease in time to peak pain relief, a decrease in time to first perceptible pain relief, a decrease in time to
- traumatic brain injury can refer to a neurological condition characterized as an acquired brain injury which occurs when a sudden trauma causes damage to the brain.
- treating traumatic brain injury can refer to a reduction of the symptoms of traumatic brain injury.
- treating traumatic brain injury refers to an increase in Glasgow Outcome Scale (GOS) score, an increase in time to worsening of Glasgow Outcome Scale (GOS) score, an increase in Glasgow Coma Scale (GCS) score, an increase in time to worsening of Glasgow Coma Scale (GCS) score, an increase in Quality of Life after Brain Injury (QOLIBRI) score, an increase in time to worsening of Quality of Life after Brain Injury (QOLIBRI) score, a decrease in Neuropsychiatric Inventory Clinician Rating Scale (NPI-C) sub-scale scores for clinical impression severity, aggression, agitation, irritability/lability and/or disinhibition, an increase in time to worsening of Neuropsychiatric Inventory Clinician Rating Scale (NPI-C) sub-scale scores for clinical impression severity, aggression, agitation, irritability/lability and/or disinhibition, an increase in time to
- said increases, decreases and reductions of scores and/or presentations of symptoms of a condition other than major depressive disorder can be assessed in comparison to the scores and/or presentations of symptoms as identified before treatment is initiated, i.e. baseline.
- said increases, decreases and reductions of scores and/or presentations of symptoms condition other than major depressive disorder can be assessed in comparison to the scores and/or presentations of symptoms as identified in a different treatment group.
- the different treatment group is a second medication other than ketamine or esketamine.
- the different treatment group is a placebo.
- the methods of the disclosure will exhibit an acceptable safety and/or tolerability profile. That is, the benefits achieved using the methods of the disclosure will outweigh any safety and/or tolerability considerations exhibited by using the disclosed methods, as compared to placebo. In other aspects, the benefits achieved using the methods of the disclosure will outweigh any safety and/or tolerability considerations exhibited by using the disclosed methods, as compared to other methods of treating conditions other than major depressive disorder. Other methods of treating a condition other than major depressive disorder, include other methods of using ketamine and esketamine.
- the benefits achieved using the methods of the disclosure will outweigh any adverse events including, for example, untoward changes in hematology, biochemistry, urinalysis, immunological parameters, physical examination findings, blood pressure, and/or heart rate, as compared to placebo.
- the benefits achieved using the methods of the disclosure will outweigh any adverse events including, for example, changes in hematology, biochemistry, urinalysis, immunological parameters, physical examination findings, blood pressure, and/or heart rate, as compared to other methods of treating a condition other than major depressive disorder.
- DSST Digit Symbol Substitution Test
- MOAA/S Modified Observer’s Alertness/Sedation Scale
- CADSS Clinician-Administered Dissociative States
- DSST Digit Symbol Substitution Test
- MOAA/S Modified Observer’s Alertness/Sedation Scale
- ketamine shall refer to the chemical compound dl 2-(2- chlorophenyl)-2(methylamino) cyclohexanone, or a pharmaceutically acceptable salt thereof.
- the term “esketamine” shall refer to the (S)-enantiomer of ketamine also known as the chemical compound (2S)-2-(2-Chlorophenyl)-2-(methylamino) cyclohexanone, or a pharmaceutically acceptable salt thereof.
- the term “esketamine” shall be understood to be to the exclusion of the compound as found, without an enantiomeric excess, in ketamine, or a pharmaceutically acceptable salt thereof.
- the esketamine, or a pharmaceutically acceptable salt thereof is the hydrochloride salt of esketamine, i.e., esketamine hydrochloride.
- (R) -ketamine shall refer to the (R)-enantiomer of ketamine also known as the chemical compound (2R)-2-(2-Chlorophenyl)-2-(methylamino) cyclohexanone, or a pharmaceutically acceptable salt thereof.
- (R)-ketamine shall be understood to be to the exclusion of the compound as found, without an enantiomeric excess, in ketamine, or a pharmaceutically acceptable salt thereof.
- (S)-norketamine shall refer to the (S)-enantiomer of norketamine also known as the chemical compound (2S)-2-(2-Chlorophenyl)-2-(amino) cyclohexanone, or a pharmaceutically acceptable salt thereof.
- (S)- norketamine shall be understood to be to the exclusion of the compound as found, without an enantiomeric excess, in norketamine, or a pharmaceutically acceptable salt thereof.
- (2S,6S)-OH-norketamine shall refer to the (2S,6S)- enantiomer of hydroxynorketamine also known as the chemical compound (2S,6S)-2-Amino-2-(2- chlorophenyl)-6-hydroxycyclohexanone, or a pharmaceutically acceptable salt thereof.
- the term “(2S,6S)-OH-Norketamine” shall be understood to be to the exclusion of the compound as found, without an enantiomeric excess, in hydroxynorketamine, or a pharmaceutically acceptable salt thereof.
- the chemical compounds described herein according to the invention are also intended to include such compounds wherein the molecular structures include isotopes of carbon, hydrogen and nitrogen atoms occurring on those structures.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include deuterium.
- isotopes of carbon include C-13.
- Isotopes of nitrogen include N-15.
- any hydrogen atom or group of hydrogen atoms could suitably be replaced by an isotope of hydrogen, i.e., deuterium;
- any carbon atom or group of carbon atoms could suitably be replaced by an isotope of carbon, i.e., 13 C;
- any nitrogen atom or group of nitrogen atoms could suitably be replaced by an isotope of nitrogen, i.e., 15 N.
- the term “treatment regimen” shall refer to time period during which the human patient, in need thereof, will be treated by more than one, either daily or intermittent, administrations of esketamine.
- the treatment regimen will extend for at least 28 days.
- the treatment regimen will extend for at least 30 days.
- the treatment regimen will be for 28 days to about 365 days.
- the treatment regimen will be for 28 days to about 730 days.
- the treatment regimen will extend for at least one month.
- the treatment regimen will extend for at least 1 year (365 days).
- the treatment regimen will extend for at least about 730 days, that is, at least about 2 years.
- the treatment regimen varies over the course of the 28 to about 730 days (i.e., about two years).
- a medical professional skilled in the art of psychiatry will be able to determine the administration regimen over the 28 to about 730 days ( e.g . about two years).
- the reduction of the symptoms of a condition other than major depressive disorder are on or after day 28 of the treatment regimen.
- the reduction of the symptoms of a condition other than major depressive disorder are on or after day 30 of the treatment regimen.
- the reduction of the symptoms of a condition other than major depressive disorder are on or after day 365 of the treatment regimen.
- the reduction of the symptoms of a condition other than major depressive disorder are on or after day 730 of the treatment regimen.
- the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 7 days of treatment.
- the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 14 days of treatment.
- the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 21 days of treatment.
- the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 28 days of treatment.
- the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 365 days of treatment. In another embodiment, the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 730 days of treatment.
- the reduction of the symptoms of a condition other than major depressive disorder are on or after day 28 of the treatment regimen and are in comparison to the scores and/or presentations of symptoms as identified before treatment is initiated, i.e. baseline.
- the reduction of the symptoms of a condition other than major depressive disorder are on or after day 28 of the treatment regimen and are in comparison to the scores and/or presentations of symptoms as identified in a different treatment group.
- the different treatment group is a second medication other than ketamine or esketamine.
- the different treatment group is a placebo.
- the reduction of the symptoms of a condition other than major depressive disorder are on or after day 30 of the treatment regimen. In another embodiment, the reduction of the symptoms of a condition other than major depressive disorder are on or after day 365 of the treatment regimen. In another embodiment, the reduction of the symptoms of a condition other than major depressive disorder are on or after day 730 of the treatment regimen. In one embodiment, the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 7 days of treatment. In another embodiment, the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 14 days of treatment.
- the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 21 days of treatment. In another embodiment, the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 28 days of treatment. In another embodiment, the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 365 days of treatment. In another embodiment, the treatment regimen results in a reduction of the symptoms of a condition other than major depressive disorder are after at least 730 days of treatment.
- the reduction or prevention of the symptoms of bipolar disorder are on or after day 28 of the treatment regimen. In another embodiment, the reduction or prevention of the symptoms of bipolar disorder are on or after day 30 of the treatment regimen. In another embodiment, the reduction or prevention of the symptoms of bipolar disorder are on or after day 365 of the treatment regimen. In another embodiment, the reduction or prevention of the symptoms of bipolar disorder are on or after day 730 of the treatment regimen. In one embodiment, the treatment regimen results in a reduction or prevention of the symptoms of bipolar disorder are after at least 7 days of treatment. In another embodiment, the treatment regimen results in a reduction or prevention of the symptoms of bipolar disorder are after at least 14 days of treatment.
- the treatment regimen results in a reduction or prevention of the symptoms of bipolar disorder are after at least 21 days of treatment. In another embodiment, the treatment regimen results in a reduction or prevention of the symptoms of bipolar disorder are after at least 28 days of treatment. In another embodiment, the treatment regimen results in a reduction or prevention of the symptoms of bipolar disorder are after at least 365 days of treatment. In another embodiment, the treatment regimen results in a reduction or prevention of the symptoms of bipolar disorder are after at least 730 days of treatment.
- the reduction or prevention of the symptoms of bipolar disorder are on or after day 28 of the treatment regimen and are in comparison to the scores and/or presentations of symptoms as identified before treatment is initiated, i.e. baseline.
- the reduction or prevention of the symptoms of bipolar disorder are on or after day 28 of the treatment regimen and are in comparison to the scores and/or presentations of symptoms as identified in a different treatment group.
- the different treatment group is a second medication other than ketamine or esketamine.
- the different treatment group is a placebo.
- the subject suffering from bipolar disorder is diagnosed as having a MADRS score of greater than 24 immediately prior to starting the treatment regimen. In one embodiment, the subject suffering from bipolar disorder is diagnosed as having a major depressive episode lasting longer than four weeks immediately prior to starting the treatment regimen. In another embodiment, the subject suffering from bipolar disorder is diagnosed as having a major depressive episode lasting less than twelve months immediately prior to starting the treatment regimen. In another embodiment, the subject suffering from bipolar disorder is diagnosed as having a major depressive episode lasting longer than four weeks and less than twelve months immediately prior to starting the treatment regimen.
- the patient is diagnosed as having a major depressive episode lasting longer than four weeks and/or less than twelve months based on their MADRS score, a similar psychometric score or in patient self-reporting of their global impression of improvement as assessed immediately prior to starting the treatment regimen.
- the subject suffering from bipolar disorder is diagnosed as having been rapidly cycling in the previous twelve months. In another embodiment, the subject suffering from bipolar disorder is diagnosed as not having been rapidly cycling in the previous twelve months.
- the term “rapid cycling” or “rapidly cycling” refers to the situation wherein the subject suffering from bipolar is identified as having at least four episodes, whether manic, hypomanic, or major depressive, in the previous twelve months.
- a parameter range includes 1.1 ng/ml, 1.2 ng/ml, 1.3 ng/ml, etc. up to 30 ng/ml.
- 0.1-2.5mg/day includes 0.1 mg/day, 0.2 mg/day, 0.3 mg/day, etc. up to 2.5 mg/day.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by orally administering to said patient of an oral dosage form comprising about 5 mg to about 40 mg, preferably 5 mg to 40 mg, of esketamine over a treatment regimen of at least 28 days.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by orally administering to said patient of an oral dosage form comprising about 5 mg to about 40 mg, preferably 5 mg to 40 mg, of esketamine over a treatment regimen of at least 28 days.
- oral dosage forms of the disclosure include esketamine, i.e., esketamine as a free base.
- oral dosage forms of the disclosure include pharmaceutically acceptable salts of esketamine.
- amounts of esketamine present in the oral dosage forms of the disclosure refer to amounts of esketamine free base.
- the oral dosage form comprises esketamine free base
- “10 mg of esketamine” refers to 10 mg of the esketamine free base in the oral dosage form.
- the oral dosage form comprises a pharmaceutically acceptable salt of esketamine, such as esketamine hydrochloride
- esketamine such as esketamine hydrochloride
- 10 mg of esketamine refers to 10 mg esketamine free base, based on 11.53 mg of esketamine hydrochloride in the oral dosage form.
- the oral administration to said patient is of an oral dosage form comprising about 5 mg of esketamine, preferably 5 mg of esketamine. In another preferred embodiment of the invention, the oral administration to said patient is of an oral dosage form comprising about 10 mg of esketamine, preferably 10 mg of esketamine. In another preferred embodiment, the oral administration to said patient is of an oral dosage form comprising about 20 mg of esketamine, preferably 20 mg of esketamine. In another preferred embodiment, the oral administration to said patient is of an oral dosage form comprising about 30 mg of esketamine, preferably 30 mg of esketamine. In yet another preferred embodiment, the oral administration to said patient is of an oral dosage form comprising about 40 mg of esketamine, preferably 40 mg of esketamine.
- a therapeutic effect of repeated oral dosing of esketamine in the treatment of a condition other than major depressive disorder can be achieved by either administering higher doses of the drug at longer intervals or administering lower doses of the drug at shorter intervals.
- the present invention allows for equivalent exposure over time of the drug and its metabolites and lower peak concentrations, reduces the overall risk of genotoxic events and improves the clinical safety profile.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, wherein the esketamine Cmax of said administration is 30 ng/ml or less.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, wherein the esketamine Cmax of said administration is 30 ng/ml or less.
- Cmax shall refer to the mean (average) observed maximum plasma concentration assayed after any single administration.
- the method disclosed herein further comprises measuring plasma levels in the patient.
- the esketamine Cmax of said administration is 30 ng/ml or less, 29 ng/ml or less, 28 ng/ml or less, 27 ng/ml or less, 26 ng/ml or less, 25 ng/ml or less, 24 ng/ml or less, 23 ng/ml or less, 22 ng/ml or less, 21 ng/ml or less, 20 ng/ml or less, 19 ng/ml or less, 18 ng/ml or less, 17 ng/ml or less, 16 ng/ml or less, 15 ng/ml or less, 14 ng/ml or less, 13 ng/ml or less, 12 ng/ml or less, 11 ng/ml or less, 10 ng/ml or less, 9 ng/ml or less, 8 ng/ml or less, 7 ng/ml or less, 6 ng/ml or less, 5 ng/ml or
- the esketamine Cmax of said administration is 30 ng/ml or less. In another preferred embodiment of the invention, the esketamine Cmax of said administration is 15 ng/ml or less. In one preferred embodiment of the invention, the esketamine Cmax of said administration is between 15 ng/mL and 30 ng/mL. In one preferred embodiment of the invention, the esketamine Cmax of said administration is between 10 ng/mL and 15 ng/mL. In one preferred embodiment of the invention, the esketamine Cmax of said administration is between 5 ng/mL and 15 ng/mL. In one preferred embodiment of the invention, the esketamine Cmax of said administration is between 11 ng/mL and 13 ng/mL.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, for example, 5 mg to 40 mg of esketamine, wherein the esketamine AUCo-t of said administration is 60 ng*h/ml or less.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, for example, 5 mg to 40 mg of esketamine, wherein the esketamine AUCo-t of said administration is 60 ng*h/ml or less.
- AUC shall refer to the area under the plasma concentration/time curve after any single administration.
- AUCo-t shall refer to the area under the plasma concentration/time curve from time 0 to the last quantifiable concentration after any single administration and the term “AUCO-inf” shall refer to the area under the plasma concentration/time curve from time 0 until the extrapolated concentration at infinity after any single administration.
- AUCtau shall refer to the area under the plasma concentration/time curve over the steady state dosing interval.
- the esketamine AUCo-t of said administration is 60 ng*h/ml, 59 ng*h/ml, 58 ng*h/ml, 57 ng*h/ml, 56 ng*h/ml, 55 ng*h/ml, 54 ng*h/ml, 53 ng*h/ml,
- the esketamine AUCo-t of said administration is 60 ng*h/ml or less. In another preferred embodiment of the invention, the esketamine AUCo-t of said administration is 30 ng*h/ml or less.
- the esketamine AUCo-t of said administration is between 30 ng*h/ml and 60 ng*h/ml. In one preferred embodiment of the invention, the esketamine AUCo-t of said administration is between 15 ng*h/ml and 30 ng*h/ml.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of a dosage form, wherein said dosage form provides for an (S)-norketamine Cmax of 150 ng/ml or less.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of a dosage form, wherein said dosage form provides for an (S)-norketamine Cmax of 150 ng/ml or less.
- the (S)-norketamine Cmax of said administration is 150 ng/ml or less, 145ng/ml or less, 140ng/ml or less, 139ng/ml or less, 138ng/ml or less, 137ng/ml or less, 136ng/ml or less, 135ng/ml or less, 134ng/ml or less, 133ng/ml or less, 132ng/ml or less, 131ng/ml or less, 130ng/ml or less, 129ng/ml or less, 128ng/ml or less, 127ng/ml or less, 126ng/ml or less, 125ng/ml or less, 120ng/ml or less, 115ng/ml or less, HOng/ml or less, 105ng/ml or less, lOOng/ml or less, 95ng/ml or less, 90ng/ml or less, 85ng/ml or less,
- 62ng/ml or less 61ng/ml or less, 60ng/ml or less, 55ng/ml or less, 50ng/ml or less, 45ng/ml or less,
- the (S)- norketamine Cmax of said administration is 150ng/ml or less. In another preferred embodiment of the invention, the (S)-norketamine Cmax of said administration is 75ng/ml or less. In another preferred embodiment of the invention, the (S)-norketamine Cmax of said administration is 35ng/ml or less. In another preferred embodiment of the invention, the (S)-norketamine Cmax of said administration is 20ng/ml or less. In one preferred embodiment of the invention, the (S)-norketamine Cmax of said administration is between 15 ng/mL and 150 ng/mL.
- the (S)-norketamine Cmax of said administration is between 15 ng/mL and 20 ng/mL. In another preferred embodiment of the invention, the (S)-norketamine Cmax of said administration is between 30 ng/mL and 35 ng/mL. In another preferred embodiment of the invention, the (S)- norketamine Cmax of said administration is between 60 ng/mL and 75 ng/mL. In another preferred embodiment of the invention, the (S)-norketamine Cmax of said administration is between 125 ng/mL and 140 ng/mL. In another preferred embodiment of the invention, the (S)-norketamine Cmax of said administration is between 60 ng/mL and 140 ng/mL.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of a dosage form, wherein said dosage form provides for an (S)-norketamine AUCo-t of 850 ng*h/ml or less.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of a dosage form, wherein said dosage form provides for an (S)-norketamine AUCo-t of 850 ng*h/ml or less.
- the (S)-norketamine AUCo-t of said administration is 850 ng*h/ml or less, 845 ng*h/ml or less, 840 ng*h/ml or less, 839 ng*h/ml or less, 838 ng*h/ml or less, 837 ng*h/ml or less, 836 ng*h/ml or less, 835 ng*h/ml or less, 834 ng*h/ml or less, 832 ng*h/ml or less, 831 ng*h/ml or less, 830 ng*h/ml or less, 829 ng*h/ml or less, 828 ng*h/ml or less, 827 ng*h/ml or less, 826 ng*h/ml or less, 825 ng*h/ml or less, 824 ng*h/ml or less, 823 ng*h/ml or
- the (S)-norketamine AUCo-t of said administration is 850 ng*h/ml or less. In another preferred embodiment of the invention, the (S)-norketamine AUCo-t of said administration is 420 ng*h/ml or less. In another preferred embodiment of the invention, the (S)-norketamine AUCo-t of said administration is 210 ng*h/ml or less. In another preferred embodiment of the invention, the (S)-norketamine AUCo-t of said administration is 105 ng*h/ml or less.
- the (S)- norketamine AUCo-t of said administration is between 105 ng*h/ml and 850 ng*h/ml. In another preferred embodiment of the invention, the (S)-norketamine AUCo-t of said administration is between 105 ng*h/ml and 850 ng*h/ml. In another preferred embodiment of the invention, the (S)-norketamine AUCo-t of said administration is between 102 ng*h/ml and 105 ng*h/ml. In another preferred embodiment of the invention, the (S)-norketamine AUCo-t of said administration is between 205 ng*h/ml and 210 ng*h/ml.
- the (S)-norketamine AUCo-t of said administration is between 410 ng*h/ml and 420 ng*h/ml. In another preferred embodiment of the invention, the (S)-norketamine AUCo-t of said administration is between 820 ng*h/ml and 840 ng*h/ml.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of a dosage form, wherein said dosage form provides for an (2S,6S)-OH-norketamine Cmax of 75 ng/ml or less.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of a dosage form, wherein said dosage form provides for an (2S,6S)-OH-norketamine Cmax of 75 ng/ml or less.
- the (2S,6S)-OH-norketamine Cmax of said administration is 75ng/ml or less, 74ng/ml or less, 73ng/ml or less, 72ng/ml or less, 71ng/ml or less, 70ng/ml or less, 69ng/ml or less, 68ng/ml or less, 67ng/ml or less, 66ng/ml or less, 65ng/ml or less,
- 64ng/ml or less 64ng/ml or less, 63ng/ml or less, 62ng/ml or less, 61ng/ml or less, 60ng/ml or less, 55ng/ml or less,
- 50ng/ml or less 50ng/ml or less, 45ng/ml or less, 40ng/ml or less, 35ng/ml or less, 34ng/ml or less, 33ng/ml or less,
- 32ng/ml or less 31ng/ml or less, 30ng/ml or less, 25ng/ml or less, 20ng/ml or less, 19ng/ml or less,
- the (2S,6S)-OH-norketamine Cmax of said administration is 75ng/ml or less. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine Cmax of said administration is 35ng/ml or less. In another preferred embodiment of the invention, the (2S,6S)-OH- norketamine Cmax of said administration is 20ng/ml or less. In one preferred embodiment of the invention, the (2S,6S)-OH-norketamine Cmax of said administration is between 15 ng/mL and 75 ng/mL.
- the (2S,6S)-OH-norketamine Cmax of said administration is between 15 ng/mL and 20 ng/mL. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine Cmax of said administration is between 30 ng/mL and 35 ng/mL. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine Cmax of said administration is between 60 ng/mL and 75 ng/mL.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of a dosage form, wherein said dosage form provides for an (2S,6S)-OH-norketamine AUCo-t of 850 ng*h/ml or less.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of a dosage form, wherein said dosage form provides for an (2S,6S)-OH-norketamine AUCo-t of 850 ng*h/ml or less.
- the (2S,6S)-OH-norketamine AUCo-t of said administration is 850 ng*h/ml or less, 845 ng*h/ml or less, 840 ng*h/ml or less, 839 ng*h/ml or less, 838 ng*h/ml or less, 837 ng*h/ml or less, 836 ng*h/ml or less, 835 ng*h/ml or less, 834 ng*h/ml or less, 832 ng*h/ml or less, 831 ng*h/ml or less, 830 ng*h/ml or less, 829 ng*h/ml or less, 828 ng*h/ml or less, 827 ng*h/ml or less, 826 ng*h/ml or less, 825 ng*h/ml or less, 824 ng*h/ml or less, 823 ng**h/ml or less, 845
- the (2S,6S)-OH-norketamine AUCo-t of said administration is 850 ng*h/ml or less. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine AUCo-t of said administration is 420 ng*h/ml or less. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine AUCo-t of said administration is 210 ng*h/ml or less. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine AUCo-t of said administration is 105 ng*h/ml or less.
- the (2S,6S)-OH-norketamine AUCo-t of said administration is between 105 ng*h/ml and 850 ng*h/ml. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine AUCo-t of said administration is between 105 ng*h/ml and 850 ng*h/ml. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine AUCo-t of said administration is between 102 ng*h/ml and 105 ng*h/ml.
- the (2S,6S)-OH-norketamine AUCo-t of said administration is between 205 ng*h/ml and 210 ng*h/ml. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine AUCo- t of said administration is between 410 ng*h/ml and 420 ng*h/ml. In another preferred embodiment of the invention, the (2S,6S)-OH-norketamine AUCo-t of said administration is between 820 ng*h/ml and 840 ng*h/ml.
- the present invention is further directed to a method of treating a condition other than major depressive disorder, in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg, for example of esketamine, 5 mg to 40 mg, of esketamine, wherein the administration is daily.
- the present invention is further directed to a method of treating bipolar disorder, in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg, for example of esketamine, 5 mg to 40 mg, of esketamine, wherein the administration is daily.
- the daily administration of esketamine is provided in a single daily dose. In another embodiment of the invention, the daily administration of esketamine is provided in two doses, in three doses, or in four doses, each dose being spread about equally over the 24 hour period.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising 5 mg to 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, wherein the administration is intermittent over the treatment regimen.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising 5 mg to 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, wherein the administration is intermittent over the treatment regimen.
- the intermittent administration is once every second day to about once a month or once every 4 weeks.
- the intermittent administration is once every second day, once every third day, twice a week, once every fourth day, once every fifth day, once every sixth day, once a week, once every eighth day, once every ninth day, once every tenth day, once every eleventh day, once every twelfth day, once every thirteenth day, once every two weeks, once every three weeks or once a month.
- the intermittent administration is twice a week.
- the intermittent administration is once a week.
- the intermittent administration is once a month.
- the intermittent administration is once every 4 weeks.
- frequency of the intermittent administration can vary over the time period of the treatment regimen. In a preferred embodiment of the invention, the frequency of the intermittent administration is gradually reduced over the time period of the treatment regimen. In a more preferred embodiment of the invention, the frequency of the intermittent administration is reduced from twice a week to once a week. In another preferred embodiment of the invention, the frequency of the intermittent administration is reduced from once a week to once every two weeks. In an even more preferred embodiment of the invention, the frequency of the intermittent administration is reduced from twice a week to once a week to once every two weeks. In another preferred embodiment of the invention, the frequency of the intermittent administration is maintained consistently over the time period of the treatment regimen.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, over a treatment regimen of at least 28 days wherein the administration is self- administered.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, over a treatment regimen of at least 28 days wherein the administration is self-administered.
- self-administered refers to administration wherein the patient is responsible for taking the medication and is not assisted during the oral administration of the oral dosage form by a healthcare professional.
- one or more of the administrations may be assisted by a healthcare professional and one or more of the administration may be self- administered over the treatment regimen.
- said self-administration is in the patient’s own home.
- said self-administration is at night.
- said self-administration is before the patient goes to sleep.
- the patient has no restrictions on driving in the 24 hours immediately following the oral administration of the oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine. That is, the oral administration of the oral dosage form does not result in a mental or motor impairment that negatively affects the patient’s ability to operative a motor vehicle. In the 24 hours immediately following the administration.
- the patient is restricted from driving for no more than 10 hours after the oral administration of the oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine.
- the patient is restricted from driving for no more than 8 hours after the administration.
- the patient is restricted from driving for no more than 6 hours after the administration.
- the patient is restricted from driving for no more than 2 hours after the administration.
- the patient is restricted from driving for no more than an hour after the oral administration of the oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine.
- the oral dosage form is a liquid preparation such as a suspension, elixir, or solution.
- the oral dosage forms are solid preparations, for example, powders, capsules, caplets, gelcaps, and tablets.
- the oral dosage form is a tablet, gelcap, or capsule. In a more preferred embodiment, the oral dosage form is a tablet.
- esketamine and optionally, at least one second medication other than (R)-ketamine
- pharmaceutical carriers may take a wide variety of forms depending of the form of preparation desired for administration.
- any of the usual pharmaceutical media may be employed.
- suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like.
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed.
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof by the administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, wherein the oral dosage form is an abuse deterrent formulation.
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof by the administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, wherein the oral dosage form is an abuse deterrent formulation.
- the abuse deterrent formulation is a tablet.
- Abuse deterrent tablet formulations can be prepared by methods known in the art including as found in US7955619, W02014006004, W02008033523, W02008023261, WO2016094358,
- the present invention is further directed to methods of treating a condition other than major depressive disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, further comprising the administration of a second medication other than (R)- ketamine.
- the present invention is further directed to methods of treating bipolar disorder in a human patient in need thereof by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine, further comprising the administration of a second medication other than (R)-ketamine.
- the second medication is an antidepressant or an antimanic agent or an anxiolytic drug.
- the antidepressant is selected from the group consisting of mono-amine oxidase inhibitors (MAOI), tricyclic antidepressants (TCA), serotonin specific reuptake inhibitors (SSRI), serotonin noradrenergic reuptake inhibitors (SNRI), , noradrenaline reuptake inhibitor (NRI), "natural products” (such as Kava-Kava, St. John's Wort), dietary supplement (such as s-adenosylmethionine) and others.
- MAOI mono-amine oxidase inhibitors
- TCA tricyclic antidepressants
- SSRI serotonin specific reuptake inhibitors
- SNRI serotonin noradrenergic reuptake inhibitors
- NRI noradrenaline reuptake inhibitor
- "natural products” such as Kava-Kava, St. John's Wort
- antidepressants include, but are not limited to, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, maprotiline, amoxapine, trazodone, bupropion, chlomipramine, fluoxetine, citalopram, escitalopram, sertraline, paroxetine, tianeptine, agomelatine, nefazadone, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, duloxetine, reboxetine, mirtazapine, mianserin, phenelzine, tranylcypromine, and /or moclobemide.
- the second medication is an antimanic agent.
- the antimanic agent is an anticonvulsant such as carbamazepine, gabapentin, valproic acid, lamotrigine or topiramate.
- the antimanic agent is an antipsychotic medication such as lurasidone, cariprazine, olanzapine, risperidone, quetiapine, paliperidone, lumateperone, aripiprazole or brexpiprazole.
- the antimanic agent is a mood stabilizer such as lithium or a pharmaceutically acceptable salt thereof or a calcium channel blocker.
- the antimanic agent is an anxiolytic drug such as alprazolam, bromazepam, chlordiazepoxide, clonazepam, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam, triazolam, buspirone, gepirone, ispapirone, hydroxyzine, amobarbital, pentobarbital, phenobarbital, thiopental and propranolol.
- an anxiolytic drug such as alprazolam, bromazepam, chlordiazepoxide, clonazepam, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam, triazolam, buspirone, gepirone, ispapirone, hydroxyzine, amobarbital, pentobarbital, phenobarbit
- the present invention is further directed to a method of treating a condition other than major depressive disorder in a human patient in need thereof, by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine and an antidepressant selected from the group consisting of fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, desvenlafaxine, duloxetine, and fluvoxamine and wherein the administration is daily over a treatment regimen of at least 28 days.
- an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine and an antidepressant selected from the group consisting of fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, desvenlafaxine, duloxetine, and fluvoxamine and wherein the administration is daily over a
- the present invention is further directed to a method of treating bipolar disorder in a human patient in need thereof, by the oral administration to said patient of an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine and an antidepressant selected from the group consisting of fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, desvenlafaxine, duloxetine, and fluvoxamine and wherein the administration is daily over a treatment regimen of at least 28 days.
- an oral dosage form comprising about 5 mg to about 40 mg of esketamine, preferably 5 mg to 40 mg of esketamine and an antidepressant selected from the group consisting of fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, desvenlafaxine, duloxetine, and fluvoxamine and wherein the administration is daily over a treatment regimen of at least 28
- Example 1 In vitro chromosomal aberration assay
- Example la esketamine
- HPBL peripheral blood lymphocytes
- MI mitotic index
- the definitive chromosome aberration assay evaluated HPBL cells after exposure to esketamine for 20 hours in the absence of S9 activation, or for 4 hours, either in the presence of absence of S9 activation, followed by a 16-hour recovery.
- MMC was associated with a mean MI value of 9% with structural chromosomal aberrations in 13.3% of the cells.
- CP was associated with a mean MI value of 6.2% and with structural aberrations in 10.7% of the cells.
- the results for negative controls were within the range of historical controls and the results for positive controls were statistically significant (p ⁇ 0.01, Fisher’s exact test). Thus the requirements for a valid test were fulfilled.
- cytotoxicity > 45% reduction in mitotic index relative to the vehicle control was not observed at any esketamine dose in the non-activated 4- and 20-hour treatment conditions.
- Cytotoxicity was observed at doses > 200 pg/mL in the S9-activated 4-hour exposure group.
- the doses selected for evaluation of chromosomal aberrations were 60, 120, and 238 pg/mL for the non-activated 4- and 20- hour treatment conditions; and 30, 60, and 200 pg/mL for the S9-activated 4-hour treatment condition.
- (S)-norketamine was evaluated in the in vitro mammalian chromosome aberration test using human peripheral blood lymphocytes (HPBL) in both the absence and presence of an induced metabolic activation system (the 9000g supernatant [S9] microsomal fraction of liver homogenate from rats exposed to phenobarbital/5,6-benzoflavone). Clastogenicity was evaluated by microscopic examination of HPBL in metaphase to determine the percentage of metaphase cells with numerical and/or structural chromosome aberrations.
- HPBL peripheral blood lymphocytes
- (S)-Norketamine caused no statistically significant increases in the proportion of metaphase figures containing chromosomal aberrations, at any analyzed concentration, when compared with the vehicle control. All mean values for the vehicle control (water), and all (S)-norketamine treatment concentrations were below to the laboratory historical control range, when taken at the upper 95% control limit.
- Example 2 In vivo single cell gel electrophoresis assay and mammalian erythrocyte micronucleus test of esketamine in Sprague Pawley rats
- Cell suspensions from each tissue were obtained from animals in the vehicle control group and in each of the test item groups approximately 3 hours after administration of the third dose.
- Cell suspensions from animals in the positive control group were obtained approximately 3 hours after a single dose.
- Bone marrow smears were obtained from animals in the vehicle control and in each of the test item groups approximately 3 hours after administration of the third dose.
- the benchmark dose (BMD50) was modelled based on the mean and median tail intensity values respectively, for the male and female rats following exposure to esketamine.
- the Hill and exponential models provided a suitable fit to the in vivo comet tail intensity data, which is consistent with the non-linear dose response.
- the lower benchmark dose (BMDL50) metrics were calculated to be 9.83mg/kg/day in female rats and 27.31mg/kg/day in male rats, both using the ‘single slide median Tail Intensity’ which were lower and more conservative than those derived when using the ‘single slide mean Tail Intensity’.
- POD point of departure
- TK toxicokinetics
- Toxicity was evaluated based on mortality, clinical observations, body weights, food consumption, ophthalmology, motor activity, functional observational battery, clinical pathology (clinical chemistry, hematology, coagulation and urinalysis), organ weights, anatomic (macroscopic or microscopic) pathology.
- Toxicokinetic animals (3/sex/Group 1; 6/sex/Groups 2, 3, and 4) were similarly dosed and bled on Day 1 and during Week 4 for toxicokinetic analysis.
- Esketamine exposure increased in a generally dose-proportional manner in males and in a slightly greater than dose-proportional manner in females over the dose ranges of 6 to 30 mg/kg/day for males and 2 to 20 mg/kg/day for females. After normalization for dose level differences, males had lower exposures than females. Exposures were similar on Day 28 compared to Day 1, with the exception of Cmax in females, which was higher on Day 28. The results of the esketamine exposure at day 1 are described in Table 1, and at day 28 in Table 2.
- a 104 Week carcinogenicity study of esketamine administered via oral gavage to Sprague Dawley Rats is performed to evaluate the carcinogenic potential and determine the toxicokinetics of esketamine.
- the study end-points include clinical observations, body weight changes, food consumption, bioanalytical toxicokinetic analysis, and anatomic macroscopic and microscopic pathology findings.
- Example 6 a single dose randomized open-label crossover study in healthy volunteers [00177] A randomized, open- label 4- way crossover study in 16 healthy male and female subjects was held wherein said subjects were placed in a randomly assigned order and administered esketamine. Each subject was assigned to 1 of 4 treatment sequences according to a randomization code such that 4 subjects were assigned to each treatment sequence. There was a wash-out period of at least 7 days between dosing periods with doses consisting of either oral or intravenous esketamine hydrochloride.
- the study consisted of an eligibility screening period of 28 days, 4 study periods involving administration of a single dose of esketamine hydrochloride followed by safety assessments with blood sampling for PK purposes up to 72 hours after study drug administration, discharge at 72 hours after study drug administration and a follow-up visit 7-14 days after the last PK blood sample was taken on Day 4.
- Example 7 Oral Esketamine dosage forms
- Oral dosage forms of esketamine hydrochloride were manufactured according to the procedures described in WO2016094358, which is incorporated in its entirety, herein, by reference.
- Example 5 A population PK modeling analyses was performed on the results of Example 5 to provide simulated PK data following a multiple dose regimen of the doses described herein.
- Example 7 a dose range finding multicenter double-randomized double-blind placebo-controlled study to determine the safety and efficacy 10 mg. 20 mg and 40 mg oral esketamine in depressive episodes in bipolar 1 disorder patients
- a dose range finding, double-randomized, double-blind, placebo-controlled study compares the efficacy, safety and tolerability of once daily 10, 20 or 40 mg oral esketamine to placebo treatment in 204 bipolar I subjects with major depressive episodes. All subjects remain on their current anti-depressant with no dose change during the study.
- the study comprises 3 phases, screening (Days 0 - 28), double-blind treatment (days 29 - 56) composed of two 2-week periods (period 1, period 2) and post-treatment safety follow-up (days 57 - 70) following the last study treatment administration.
- subjects are assessed for study eligibility and washed out from disallowed drugs. After being found eligible, subjects are randomized at the beginning of Period 1 using a 3 : 1 : 1 : 1 allocation scheme to receive, once daily, either placebo or 1 Omg, 20mg or 40 mg oral esketamine, respectively. At the conclusion of period 1, all subjects are blindly assessed for response based on their change in MADRS-10 score from baseline to week 2. Subjects who received placebo during period 1 are re-randomized using a 1 : 1 : 1 : 1 allocation scheme to receive in the 2 weeks (period 2) either placebo or 10 mg, 20 mg or 40 mg oral esketamine once daily, respectively.
- the re randomization is stratified by the placebo response in Period 1 (Change in MADRS ⁇ or > 50% and MADRS score ⁇ or > 18). Subjects that were on oral esketamine in period 1 remain on the drug at the same dosage for the 2 weeks of period 2.
- Subjects receive the first dose of their study drug at the study site and are then closely monitored for 3 hours to assess for potential neuropsychiatric adverse events using a comprehensive set of scales to identify sleepiness, sedation and dissociative effects. Thereafter, the subject is provided with a 1 week supply of the study drug for administration at their place of residence and instructed to take the study drug in the evening (except at the day of the weekly visit when it is taken at the study site) and not to drive until the next morning. At every subject visit, a psychiatrist evaluates the subject’s MADRS-10 score.
- the study’s primary efficacy endpoint is the change from baseline to week 2 (in the 2 periods) in 10 items Montgomery- Asberg Depression Rating Scale (MADRS-10).
- Secondary efficacy endpoints include the change from baseline Sheehan disability scale (SDS) at 2 weeks, remission rate at 2 weeks (MADRS- 10 ⁇ 10), responder rate at 2 weeks (>50% improvement in MADRS-10), change from baseline in self-rated Symptoms of Depression Questionnaire (SDQ) at 2 weeks, physician administered Clinical Global Impression Improvement (CGI-I) at 2 weeks and the change from baseline in Physician administered Clinical Global Impression Severity (CGI-S) at 2 weeks.
- SDS Sheehan disability scale
- MADRS- 10 ⁇ 10 remission rate at 2 weeks
- SDQ self-rated Symptoms of Depression Questionnaire
- CGI-I Clinical Global Impression Improvement
- CGI-S Physician administered Clinical Global Impression Severity
- Exploratory Endpoints include the change from baseline to week 4 in Montgomery- Asberg Depression Rating Scale (MADRS-10) for the subset of subjects receiving the same study drug for the 4 weeks.
- MADRS-10 Montgomery- Asberg Depression Rating Scale
- Safety and tolerability endpoints include adverse events, hematology, biochemistry and urinalysis, immunological parameters, physical examination findings, blood pressure and heart rate every 30 minutes for the 3 hours following study drug administration, 12 lead ECG findings, withdrawal rates, Digit Symbol Substitution Test (DSST), reaction time test (Cambridge COGNITION), self-administered Stanford sleepiness scale, a Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS), a Modified Observer’s Alertness/Sedation Scale (MOAA/S), a Clinician- Administered Dissociative States Scale (CADSS), a suicidality scale- Clinician-Rated Columbia Suicide Severity Rating Scale (C-SSRS), 4 items positive symptoms subscale from the Brief Psychiatric Rating Scale (BPRS) and 20 item Physician Withdrawal Checklist (PWC-20) during the follow-up period.
- DSST Digit Symbol Substitution Test
- BPIC-SS Blad
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022534833A JP2023507926A (ja) | 2019-12-30 | 2020-12-29 | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| US17/789,648 US12478592B2 (en) | 2019-12-30 | 2020-12-29 | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| US17/137,697 US20210196654A1 (en) | 2019-12-30 | 2020-12-30 | Method of treating conditions |
| US19/374,249 US20260053757A1 (en) | 2019-12-30 | 2025-10-30 | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962954790P | 2019-12-30 | 2019-12-30 | |
| US62/954,790 | 2019-12-30 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/789,648 A-371-Of-International US12478592B2 (en) | 2019-12-30 | 2020-12-29 | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| US19/374,249 Continuation US20260053757A1 (en) | 2019-12-30 | 2025-10-30 | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021137148A1 true WO2021137148A1 (en) | 2021-07-08 |
Family
ID=74106090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2020/062508 Ceased WO2021137148A1 (en) | 2019-12-30 | 2020-12-29 | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US12478592B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023507926A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021137148A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| CN118121577A (zh) | 2018-05-04 | 2024-06-04 | 感知神经科学公司 | 治疗物质滥用的方法 |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2062620A1 (de) | 1969-12-19 | 1971-07-15 | Bristol Myers Co., New York, N.Y. (V.St.A.) | Optische Isomeren und Verfahren zu ihrer Spaltung |
| US20040052731A1 (en) | 2002-07-05 | 2004-03-18 | Collegium Pharmaceuticals, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| WO2008023261A1 (en) | 2006-08-25 | 2008-02-28 | Purdue Pharma L.P. | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| WO2008033523A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs Inc. | Abuse resistant drug formulation |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2011020061A2 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papalos | Compositions and methods of for treating bipolar disorder |
| US7955619B2 (en) | 2007-08-13 | 2011-06-07 | Inspirion Delivery Technologies, Llc | Abuse resistant drugs, method of use and method of making |
| WO2014006004A1 (en) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| WO2016073653A1 (en) * | 2014-11-04 | 2016-05-12 | Amorsa Therapeutics, Inc. | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| WO2018102488A1 (en) * | 2016-11-30 | 2018-06-07 | Wolfson Philip E | Ketamine for the treatment of menstrually related symptoms |
| WO2019073408A1 (en) * | 2017-10-10 | 2019-04-18 | Douglas Pharmaceuticals Ltd. | PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS |
| WO2019126108A1 (en) | 2017-12-22 | 2019-06-27 | Janssen Pharmaceutica Nv | Esketamine for the treatment of depression |
| WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| WO2009137843A2 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| US20120225949A1 (en) * | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| US9468611B2 (en) | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| KR20220044380A (ko) | 2013-04-12 | 2022-04-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
| US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| WO2015051259A1 (en) | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
| WO2015066172A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| EP3272338B1 (en) | 2014-04-17 | 2020-09-09 | Develco Pharma Schweiz AG | Oral dosage form of ketamine |
| EP3193853A1 (en) | 2014-09-15 | 2017-07-26 | Janssen Pharmaceutica NV | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| WO2017041112A1 (en) | 2015-09-04 | 2017-03-09 | Cyprus Therapeutics, Inc. | Ketamine and cytochrome p 450 inhibitor combinations |
| EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| WO2018079693A1 (ja) | 2016-10-27 | 2018-05-03 | 国立大学法人 千葉大学 | (s)-ノルケタミンおよびその塩の医薬品としての応用 |
| EP3641742B1 (en) | 2017-06-23 | 2026-03-25 | Ketabon GmbH | Hydroxynorketamine for the use in the treatment of depression |
| CA3103440A1 (en) | 2018-06-27 | 2020-01-02 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| WO2020070706A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| EP3923920A4 (en) | 2019-08-05 | 2022-11-23 | The Ketamine Research Foundation | KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| WO2021137147A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
-
2020
- 2020-12-29 JP JP2022534833A patent/JP2023507926A/ja active Pending
- 2020-12-29 WO PCT/IB2020/062508 patent/WO2021137148A1/en not_active Ceased
- 2020-12-29 US US17/789,648 patent/US12478592B2/en active Active
- 2020-12-30 US US17/137,697 patent/US20210196654A1/en not_active Abandoned
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2062620A1 (de) | 1969-12-19 | 1971-07-15 | Bristol Myers Co., New York, N.Y. (V.St.A.) | Optische Isomeren und Verfahren zu ihrer Spaltung |
| US20040052731A1 (en) | 2002-07-05 | 2004-03-18 | Collegium Pharmaceuticals, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| WO2008023261A1 (en) | 2006-08-25 | 2008-02-28 | Purdue Pharma L.P. | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| WO2008033523A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs Inc. | Abuse resistant drug formulation |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| US7955619B2 (en) | 2007-08-13 | 2011-06-07 | Inspirion Delivery Technologies, Llc | Abuse resistant drugs, method of use and method of making |
| WO2011020061A2 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papalos | Compositions and methods of for treating bipolar disorder |
| WO2014006004A1 (en) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| WO2016073653A1 (en) * | 2014-11-04 | 2016-05-12 | Amorsa Therapeutics, Inc. | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| WO2018102488A1 (en) * | 2016-11-30 | 2018-06-07 | Wolfson Philip E | Ketamine for the treatment of menstrually related symptoms |
| WO2019073408A1 (en) * | 2017-10-10 | 2019-04-18 | Douglas Pharmaceuticals Ltd. | PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS |
| WO2019126108A1 (en) | 2017-12-22 | 2019-06-27 | Janssen Pharmaceutica Nv | Esketamine for the treatment of depression |
| WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Non-Patent Citations (3)
| Title |
|---|
| "SIB, Testing for Carcinogenicity of Pharmaceuticals", THE INTERNATIONAL CONFERENCE ON HARMONIZATION (ICH) S1 GUIDELINES S 1 A, GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS |
| AMERICAN PSYCHIATRIC ASSOCIATION: "Diagnostic and Statistical Manual of Mental Disorders", 1995 |
| S1C(R2), DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023507926A (ja) | 2023-02-28 |
| US20210196654A1 (en) | 2021-07-01 |
| US20230049897A1 (en) | 2023-02-16 |
| US12478592B2 (en) | 2025-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12336970B2 (en) | Method of treating major depressive disorder | |
| US12076300B2 (en) | Dosage regime with esketamine for treating major depressive disorder | |
| US12036189B2 (en) | Method of treating major depressive disorder | |
| US12364672B2 (en) | Esketamine for use in treating major depressive disorder | |
| US12478592B2 (en) | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions | |
| US20260053757A1 (en) | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions | |
| WO2020070547A1 (en) | Dosage regime of esketamine for treating major depressive disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20833972 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2022534833 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20833972 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10/11/2022) |
|
| WWG | Wipo information: grant in national office |
Ref document number: 17789648 Country of ref document: US |